StockData
IQVIA Holdings Inc. logo

IQVIA Holdings Inc. (IQV) company profile

IQVNYSEServices-Commercial Physical & Biological ResearchFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 9/3014% above fair value
$257.60−7.13 (-2.69%)

Close on Nov 17, 2026Market cap $42.45BP/E 31.3Yield –

About Iqvia

Services-Commercial Physical & Biological Research, SIC 8731

IQVIA provides clinical research services, healthcare intelligence, and commercial solutions to the life sciences and healthcare sectors. The company operates primarily through three reportable segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. Its portfolio includes cloud-based software platforms, real-world evidence analytics, strategic consulting, end-to-end clinical trial management, laboratory services, and stakeholder engagement programs. IQVIA serves biotechnology, pharmaceutical, medical device, and consumer health companies, as well as healthcare providers, payers, government bodies, researchers, and pharmacies.

The company operates globally with approximately 93,000 employees across more than 100 countries. It serves over 10,000 clients worldwide, maintaining clinical research networks across nearly 50 locations and conducting healthcare professional and product tracking in dozens of international markets. The provided text does not state the company's headquarters location.

Summary of the business section of Iqvia's latest annual report, written by StockData.

Company profile

Company

Legal name
IQVIA Holdings Inc.
Founded
2016
Headquarters
Durham, NC
Address
2400 Ellis Road 27703
Phone
(919) 998-2000
Website
iqvia.com
Employees
93,000, Dec 31, 2025
Industry
Services-Commercial Physical & Biological Research
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopers LLP, Raleigh, North Carolina

Stock & identifiers

Ticker
IQV
Former tickers
Q until Feb 16, 2018
Exchange
NYSE
IPO date
May 9, 2013
Shares outstanding
165M, Oct 20, 2026
Public float
$26.50B, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1478242
CUSIP
46266C105
ISIN
US46266C1053
FIGI
BBG00333FYS2
Share class FIGI
BBG00333FZ54
LEI
549300W3R20NM4KQPH86
EIN
27-1341991

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Ari BousbibSee Remarks, Director1,526,400
Eric SherbetSee Remarks20,999
James G. BerkshireSee Remarks13,558
W. Richard StaubSee Remarks13,312
Bhavik PatelSee Remarks1,348
Keriann CherofskySee Remarks2,989
Michael J. FedockSee Remarks9,472
Bernd HaasSee Remarks24,394
Alistair GrenfellSee Remarks29,669
Ronald E. BruehlmanSee Remarks55,996
John G. DanhaklDirector34,857
Morris Leslie WimsDirector2,058
Colleen A. GogginsDirector14,453
Jim FasanoDirector1,063
John M. LeonardDirector16,946
William G. Kaelin JrDirector–
Carol BurtDirector7,533
Sheila A. StampsDirector2,058
John ConnaughtonDirector1,047

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$28.13M$36.07M$8.87M$126$187
FY2024$26.73M$11.45M$6.58M$110$159
FY2023$29.15M$42.29M$4.52M$129$148
FY2022$30.14M$5.96M$5.01M$114$138
FY2021$28.62M$88.42M$4.40M$157$136
FY2020$25.58M$44.63M$2.89M$116$115

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Ari Bousbib
Chairman and Chief Executive Officer
$1.80M$15.75M$4.53M$4.97M$1.08M$28.13M+5%
Ronald E. Bruehlman
Executive Vice President, Chief Financial Officer
$905.00K$6.75M$2.25M$1.29M$244.83K$11.44M+37%
W. Richard Staub, III
President, Research & Development Solutions
$800.00K$5.25M$1.75M$943.01K$86.07K$8.83M-18%
Alistair R. Grenfell
President, Commercial Solutions
$629.91K$6.00M$2.00M$806.95K$267.74K$9.70M–
Eric M. Sherbet
Executive Vice President, General Counsel and Secretary
$665.00K$3.00M$999.95K$764.30K$71.57K$5.50M+32%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
May 9, 2013
Securities offered
23,684,210
Exchange
NYSE
First trading day
May 9, 2013
First-day close
$42.11
Lock-up ends (est.)
Nov 5, 2013

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

Corporate history

Events identified from SEC filings

DateEventDetails
Jan 5, 2024MergerRegistration of securities for a merger or exchange offer (S-4)
Nov 3, 2017Name changeName changed from Quintiles IMS Holdings, Inc. to IQVIA Holdings Inc.
Oct 3, 2016Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Sep 22, 2016Name changeName changed from Quintiles Transnational Holdings Inc. to Quintiles IMS Holdings, Inc.
Jun 3, 2016MergerRegistration of securities for a merger or exchange offer (S-4)
May 9, 2013IPOInitial public offering priced (424B4 prospectus)
May 2, 2013ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?